67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details
臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004651-20-IT (EUCTR) | 20/11/2019 | 05/01/2021 | A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease | A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON | Autosomal dominant polycystic kidney disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Bardoxolone methyl 5 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone Metile Other descriptive name: Bardoxolone methyl Product Name: Bardoxolone methyl 10 mg Product Code: [RTA 402] INN or Proposed INN: bardoxolone methyl Other descriptive name: bardoxolone methyl Product Name: Bardoxolone methyl 20 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone methyl Other descriptive name: Bardoxolone methyl Product Name: Bardoxolone methyl 15 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone Methyl Other descriptive name: Bardoxolone methyl | REATA PHARMACEUTICALS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | France;United States;Czechia;Czech Republic;Spain;Belgium;Australia;Germany;United Kingdom;Italy |